Sudarshan Pharma promoters convert warrants, lift stake to 58.93%
Promoters exercise warrants for 90 lakh shares at ₹16.98, infusing ₹11.46 crore. Stake jumps from 26.6% to 58.93%.
What's new
- Promoters converted warrants into 90 lakh equity shares at ₹16.98 each.
- Promoter holding increased to 58.93% from 26.6%.
- Company collected ₹11.46 crore as the balance subscription amount.
Why this matters
The conversion shows strong promoter commitment and drastically increases their control, reducing public float dilution. For a micro-cap with ₹842 crore market cap, the infusion of ₹15.28 crore (including earlier tranche) is about 1.8% of market cap, signalling confidence.
What we're watching
- How Sudarshan Pharma deploys the ₹15.28 crore—working capital or capex.
- Impact on EPS given the 3.6% equity dilution from 90 lakh new shares.
- Any subsequent business announcements from the promoters.
The full read
Sudarshan Pharma Industries' promoters converted warrants into 90 lakh equity shares at ₹16.98 each, bringing in ₹11.46 crore as the final installment. Total proceeds reached about ₹15.28 crore. Promoter stake rose from 26.6% to 58.93%. Decisive control now. For a micro-cap pharma company with a ₹842 crore market cap, the ₹15.28 crore infusion (roughly 1.8% of market cap) is a meaningful capital injection that strengthens the balance sheet and demonstrates promoter commitment. The 3.6% equity dilution is manageable. It's a vote of confidence from those who know the business best.
Questions answered
- How many shares were allotted and at what price?
- 90 lakh equity shares were allotted at an issue price of ₹16.983 per share, following a stock-split-adjusted warrant exercise.
- What was the promoter stake before and after the conversion?
- Promoter holding rose from 26.6% to 58.93% post-allotment, reflecting a significant increase in control.
- How much money did the company receive in total from this warrant conversion?
- The total proceeds are about ₹15.28 crore, with ₹11.46 crore collected as the final tranche and the rest from an earlier tranche.
- What is the significance of this for a micro-cap company?
- The infusion equals 1.8% of the ₹842 crore market cap, exceeding the materiality threshold for micro caps. The stake increase signals promoter confidence, which may improve investor sentiment.
- What does the conversion imply for future capital structure?
- The 3.6% equity dilution is modest, and the strengthened promoter holding could reduce perceived risk. The new shares rank pari-passu with existing equity.